Status:
COMPLETED
Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment
Lead Sponsor:
Pfizer
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
To describe the direct costs related to warfarin/apixaban treatment
Detailed Description
To describe the direct costs related to warfarin/apixaban treatment during the first 6 months of the secondary stroke prevention in NVAF patients.
Eligibility Criteria
Inclusion
- Diagnosis of non-valvular atrial fibrillation (NVAF);
- New initiation of anticoagulation therapy (apixaban or warfarin) due to the ischemic event (stroke/TIA) meaning patients previously not anticoagulated due to diagnosis of NVAF;
- Indication to anticoagulation therapy as a secondary stroke prevention within 7 to 30 days after the stroke/TIA event;
- Apixaban arm: genetically determined higher sensitivity to warfarin;
- Patients whose status allowed oral treatment with apixaban/warfarin;
- Age ≥ 18;
- Access to patient´s records of the first 6 months of the warfarin/apixaban treatment.
Exclusion
- Diagnosis of valvular disease;
- Treatment with other anticoagulants in previous 6 months due to other the NVAF indication;
- Treatment or prophylaxis of deep vein thrombosis or pulmonary embolism;
- Contraindications according SmPC of Eliquis
Key Trial Info
Start Date :
August 4 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2021
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT04435769
Start Date
August 4 2020
End Date
May 31 2021
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fakultní nemocnice Motol
Prague, Czechia, 150 06